Enhabit, Inc. (EHAB)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Enhabit, Inc. (EHAB) trades at $13.66 with AI Score 48/100 (Weak). Enhabit, Inc. is a leading provider of home health and hospice services across 34 states in the U. S. Market cap: 693M, Sector: Healthcare.
Last analyzed: Feb 8, 2026Enhabit, Inc. (EHAB) Healthcare & Pipeline Overview
Enhabit, Inc. (EHAB) delivers comprehensive home health and hospice services across 34 states, offering personalized care plans and skilled medical support with a focus on patient education, pain management, and palliative care, positioning it as a key player in the growing healthcare-at-home market.
Investment Thesis
Enhabit, Inc. presents a notable research candidate within the growing home healthcare market. The company's focus on providing comprehensive home health and hospice services positions it to capitalize on the increasing demand for in-home care. While the company currently has a negative P/E ratio of -47.42 and a negative profit margin of -1.1%, the high gross margin of 48.4% indicates potential for improved profitability through operational efficiencies and strategic growth initiatives. Key value drivers include expanding its geographic footprint within the 34 states it currently operates in and leveraging technology to enhance patient care and streamline operations. Upcoming catalysts include potential acquisitions to expand service offerings and market share. The company's beta of 1.27 suggests higher volatility compared to the market, which could offer opportunities for investors seeking higher returns.
Based on FMP financials and quantitative analysis
Key Highlights
- Operates 252 home health agencies and 99 hospice agencies across 34 states as of March 31, 2022, demonstrating a significant geographic footprint.
- Gross margin of 48.4% indicates a strong ability to control the direct costs associated with providing home health and hospice services.
- Standalone operation since July 1, 2022, allowing for focused strategic initiatives and resource allocation.
- Offers a comprehensive suite of services, including patient education, pain management, wound care, and palliative care, catering to diverse patient needs.
- Market capitalization of $0.56 billion reflects the company's current valuation in the public market.
Competitors & Peers
Strengths
- Extensive network of home health and hospice agencies.
- Comprehensive suite of services catering to diverse patient needs.
- Established presence in 34 states.
- Focus on providing quality care and compassionate support.
Weaknesses
- Negative P/E ratio and profit margin.
- High beta indicating higher volatility.
- Dependence on government reimbursement policies.
- Potential challenges in integrating acquired companies.
Catalysts
- Potential acquisitions to expand geographic footprint and service offerings.
- Increasing demand for home health and hospice services due to an aging population.
- Technological advancements improving patient care and operational efficiency.
- Strategic partnerships with healthcare providers to enhance referral networks.
Risks
- Regulatory changes impacting reimbursement rates and compliance requirements.
- Increased competition from other home health and hospice providers.
- Rising labor costs and potential staffing shortages.
- Economic downturn affecting patient affordability and demand for services.
- Integration challenges associated with acquired companies.
Growth Opportunities
- Expansion within Existing Markets: Enhabit has the opportunity to deepen its market penetration within the 34 states where it currently operates. By increasing the number of home health and hospice agencies in underserved areas and expanding service offerings, Enhabit can capture a larger share of the existing market. This strategy can be executed within the next 2-3 years and is expected to drive revenue growth by 10-15% annually.
- Strategic Acquisitions: The fragmented nature of the home healthcare industry presents opportunities for Enhabit to grow through strategic acquisitions. Acquiring smaller, regional providers can expand Enhabit's geographic footprint, increase its patient base, and enhance its service capabilities. Identifying and integrating suitable acquisition targets can be achieved within the next 3-5 years, potentially adding 20-30% to the company's revenue.
- Technological Innovation: Investing in technology to improve patient care, streamline operations, and enhance data analytics can drive growth and improve profitability. Implementing telehealth solutions, electronic health records, and remote monitoring devices can improve patient outcomes and reduce costs. This initiative can be rolled out over the next 1-2 years, leading to a 5-10% reduction in operational expenses.
- Partnerships with Healthcare Providers: Collaborating with hospitals, physician groups, and managed care organizations can create referral networks and expand Enhabit's patient base. Developing integrated care models and participating in value-based care arrangements can improve patient outcomes and reduce healthcare costs. These partnerships can be established within the next 1-2 years, contributing to a 10-15% increase in patient referrals.
- Expansion of Hospice Services: As the population ages, the demand for hospice services is expected to increase significantly. Enhabit can capitalize on this trend by expanding its hospice service offerings and increasing the number of hospice agencies it operates. Focusing on providing compassionate and comprehensive end-of-life care can enhance Enhabit's reputation and attract more patients. This expansion can be pursued over the next 3-5 years, potentially doubling the company's hospice revenue.
Opportunities
- Expansion within existing markets.
- Strategic acquisitions to increase market share.
- Technological innovation to improve patient care and reduce costs.
- Partnerships with healthcare providers to expand referral networks.
Threats
- Regulatory changes and reimbursement pressures.
- Increased competition from other home health and hospice providers.
- Potential for rising labor costs and staffing shortages.
- Economic downturn impacting patient affordability and demand.
Competitive Advantages
- Established network of 252 home health agencies and 99 hospice agencies across 34 states.
- Comprehensive suite of services, including home health and hospice care.
- Strong reputation for providing quality care and compassionate support.
- Relationships with healthcare providers and referral networks.
About EHAB
Enhabit, Inc., headquartered in Dallas, Texas, is a prominent provider of home health and hospice services in the United States. Officially incorporated in 2014, the company underwent a name change from Encompass Health Home Health Holdings, Inc. in March 2022, marking a new chapter in its corporate identity. A significant milestone occurred on July 1, 2022, when Enhabit began operating as a standalone entity, allowing it to focus exclusively on its core business. Enhabit's comprehensive suite of home health services includes patient education, pain management, wound care, cardiac rehabilitation, infusion therapy, and skilled observation. The company also provides specialized practices for managing chronic conditions such as diabetes, hypertension, arthritis, Alzheimer's disease, and Parkinson's disease. Therapy services, including physical, occupational, and speech therapy, are integral to their offerings. Enhabit's hospice services focus on providing comfort and support to terminally ill patients and their families, encompassing pain and symptom management, palliative counseling, social worker visits, spiritual guidance, and bereavement support. As of March 31, 2022, Enhabit operated 252 home health agencies and 99 hospice agencies across 34 states, demonstrating its extensive reach and commitment to delivering quality care in diverse communities.
What They Do
- Provides in-home patient education to help individuals manage their health conditions.
- Offers pain management services to alleviate discomfort and improve quality of life.
- Delivers wound care and dressing changes to promote healing and prevent infections.
- Provides cardiac rehabilitation programs to help patients recover from heart conditions.
- Administers infusion therapy and pharmaceutical treatments in the comfort of patients' homes.
- Offers skilled observation and assessment services to monitor patients' health status.
- Provides hospice care, including palliative and bereavement counseling for terminally ill patients and their families.
Business Model
- Generates revenue by providing home health services to patients in their homes.
- Receives payments from Medicare, Medicaid, private insurance companies, and patients.
- Offers hospice services for terminally ill patients, providing end-of-life care and support.
- Operates a network of home health and hospice agencies across 34 states.
Industry Context
Enhabit operates within the expanding home healthcare industry, driven by an aging population and a growing preference for receiving medical care in the comfort of one's home. The market is characterized by increasing demand for personalized and cost-effective healthcare solutions. Enhabit competes with other home health and hospice providers, including AGL, AUNA, AUTL, CBLL, and CCRN. The industry is also subject to regulatory changes and reimbursement policies, which can significantly impact profitability. As the population ages, the demand for home health and hospice services is expected to continue growing, presenting both opportunities and challenges for Enhabit.
Key Customers
- Individuals requiring medical care in their homes due to illness, injury, or chronic conditions.
- Terminally ill patients seeking comfort and support through hospice services.
- Family members and caregivers of patients receiving home health and hospice care.
- Hospitals and physician groups referring patients for post-acute care services.
Financials
Chart & Info
Enhabit, Inc. (EHAB) stock price: $13.66 (+0.01, +0.07%)
Latest News
-
How The Enhabit (EHAB) Story Is Shifting After The Kinderhook US$13.80 Cash Offer
Yahoo! Finance: EHAB News · Mar 27, 2026
-
Comparing Enhabit (NYSE:EHAB) & Selectis Health (OTCMKTS:GBCS)
defenseworld.net · Mar 25, 2026
-
Enhabit (EHAB) Q3 2025 Earnings Call Transcript
Yahoo! Finance: EHAB News · Mar 18, 2026
-
Enhabit (EHAB) Q1 2025 Earnings Call Transcript
Yahoo! Finance: EHAB News · Mar 18, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EHAB.
Price Targets
Consensus target: $13.10
MoonshotScore
What does this score mean?
The MoonshotScore rates EHAB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
How The Enhabit (EHAB) Story Is Shifting After The Kinderhook US$13.80 Cash Offer
Comparing Enhabit (NYSE:EHAB) & Selectis Health (OTCMKTS:GBCS)
Enhabit (EHAB) Q3 2025 Earnings Call Transcript
Enhabit (EHAB) Q1 2025 Earnings Call Transcript
Common Questions About EHAB (Healthcare)
What does Enhabit, Inc. do?
Enhabit, Inc. is a leading provider of home health and hospice services in the United States, operating across 34 states. The company delivers a comprehensive range of services, including patient education, pain management, wound care, cardiac rehabilitation, and infusion therapy. Enhabit also offers specialized programs for managing chronic conditions and provides hospice care for terminally ill patients and their families. The company generates revenue through payments from Medicare, Medicaid, private insurance, and direct patient payments, focusing on delivering personalized care in the comfort of patients' homes.
Is EHAB stock worth researching?
Evaluating EHAB requires a balanced perspective. While the company's negative P/E ratio and profit margin raise concerns, its high gross margin suggests potential for improved profitability. The increasing demand for home healthcare services and Enhabit's strategic growth initiatives, such as acquisitions and technological innovation, present opportunities for future growth. Investors should carefully consider the company's financial performance, industry trends, and competitive landscape before making an investment decision, weighing the potential risks and rewards associated with EHAB stock.
What are the main risks for EHAB?
Enhabit faces several key risks, including regulatory changes impacting reimbursement rates, increased competition from other home health and hospice providers, and rising labor costs. Economic downturns could also affect patient affordability and demand for services. Additionally, the company faces integration challenges associated with acquired companies. These risks could negatively impact Enhabit's financial performance and growth prospects. Careful monitoring of these factors is crucial for assessing the company's long-term viability and investment potential.
What are the key factors to evaluate for EHAB?
Enhabit, Inc. (EHAB) currently holds an AI score of 48/100, indicating low score. Analysts target $13.10 (-4% from $13.66). Key strength: Extensive network of home health and hospice agencies. Primary risk to monitor: Regulatory changes impacting reimbursement rates and compliance requirements. This is not financial advice.
How frequently does EHAB data refresh on this page?
EHAB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EHAB's recent stock price performance?
Recent price movement in Enhabit, Inc. (EHAB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $13.10 implies 4% downside from here. Notable catalyst: Extensive network of home health and hospice agencies. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EHAB overvalued or undervalued right now?
Determining whether Enhabit, Inc. (EHAB) is overvalued or undervalued requires examining multiple metrics. Analysts target $13.10 (-4% from current price), suggesting analysts see the stock near fair value. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EHAB?
Before investing in Enhabit, Inc. (EHAB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data based on available information as of 2022.
- Future performance is subject to market conditions and company-specific factors.